STOCK TITAN

Ascendis Pharma A/S - ASND STOCK NEWS

Welcome to our dedicated news page for Ascendis Pharma A/S (Ticker: ASND), a resource for investors and traders seeking the latest updates and insights on Ascendis Pharma A/S.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Ascendis Pharma A/S's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Ascendis Pharma A/S's position in the market.

Rhea-AI Summary
Ascendis Pharma reports positive results from enliGHten trial of TransCon hGH
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Ascendis Pharma launches SKYTROFA in Germany for the treatment of growth failure in children and adolescents with growth hormone deficiency.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.71%
Tags
none
-
Rhea-AI Summary
Ascendis Pharma receives positive CHMP opinion for TransCon PTH
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.15%
Tags
none
Rhea-AI Summary
Ascendis Pharma announces Q2 2023 financial results and business updates
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.24%
Tags
earnings
-
Rhea-AI Summary
Ascendis Pharma and Royalty Pharma enter $150 million synthetic royalty funding agreement for SKYTROFA
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.24%
Tags
none
-
Rhea-AI Summary
Approximately 50% of Phase 3 PaTHway Trial patients with eGFR < 60 mL/min/1.73m2 receiving TransCon PTH experienced eGFR improvement to above 60 mL/min/1.73m2, suggesting improved kidney function. Patients treated with TransCon PTH experienced a mean increase in eGFR of 7.9 mL/min/1.73m2 at Week 26 and a mean increase of 8.9 mL/min/1.73m2 at Week 52 compared to baseline. Patients with eGFR < 60 at baseline experienced a mean increase in eGFR of 11.5 mL/min/1.73m2 at Week 52. This data shows promise for a major improvement in treatment opportunities and outcomes for people living with hypoparathyroidism.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.24%
Tags
none
Rhea-AI Summary
Ascendis Pharma to participate in three upcoming investor conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2%
Tags
conferences
-
Rhea-AI Summary
Ascendant Resources announces results of annual and special meeting of shareholders
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Ascendant Resources announces results of annual and special meeting of shareholders
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2%
Tags
none
Rhea-AI Summary
Ascendis Pharma A/S (Nasdaq: ASND) to report Q2 2023 financial results and business update on September 5, 2023. Conference call and webcast to discuss financial results and operations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.31%
Tags
conferences earnings
Ascendis Pharma A/S

Nasdaq:ASND

ASND Rankings

ASND Stock Data

8.40B
56.16M
0.76%
107.84%
5.29%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Denmark
Tuborg Boulevard 5

About ASND

ascendis pharma a/s is a biotechnology company located in 12 tuborg blvd., hellerup, capital region of denmark, denmark.